Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

17.86
0.0000
Post-market: 17.860.00000.00%19:30 EDT
Volume:2.13M
Turnover:38.05M
Market Cap:56.84B
PE:-56.09
High:17.89
Open:17.85
Low:17.78
Close:17.86
52wk High:19.10
52wk Low:12.99
Shares:3.18B
Float Shares:3.09B
Volume Ratio:0.91
T/O Rate:0.07%
Dividend:0.63
Dividend Rate:3.55%
EPS(TTM):-0.3184
EPS(LYR):-0.3042
ROE:-2.26%
ROA:2.69%
PB:1.19
PE(LYR):-58.70

Loading ...

TD Cowen Sticks to Its Buy Rating for Takeda Pharmaceutical Company (TAK)

TIPRANKS
·
Jun 04

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

MT Newswires Live
·
Jun 01

Takeda Expands Maribavir Into Pediatric CMV, Extending Long-Term Upside Potential

TIPRANKS
·
May 23

Takeda Expands Real-World Data on OBIZUR, Supporting Its Rare Disease Strategy

TIPRANKS
·
May 23

Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case

MT Newswires Live
·
May 19

Jury finds Takeda caused about $885M in damages over generic delay, Reuters says

TIPRANKS
·
May 19

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

MT Newswires Live
·
May 19

Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says

TIPRANKS
·
May 19

Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says

TIPRANKS
·
May 19

Justice Department announces $13.67M civil settlement with Takeda

TIPRANKS
·
May 15

Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million

Dow Jones
·
May 15

Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring

Reuters
·
May 14

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook

MT Newswires Live
·
May 13

Press Release: Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Dow Jones
·
May 13

Takeda Pharmaceutical Co Ltd expected to post earnings of JPY117.96 a share - Earnings Preview

Reuters
·
May 11

Immigration Uncovers Trading Scam in Batam, 210 Foreigners Nabbed

Tempo
·
May 09

Takeda Advances TAK-279 Into Phase 2a Crohn’s Study, Signaling Long-Term GI Growth Ambitions

TIPRANKS
·
May 08

Takeda Advances Pediatric ENTYVIO Study, Supporting Long-Term Growth Potential

TIPRANKS
·
May 08